Entrapment of Peptidoglycans and Adamantyltripeptides into Liposomes: An HPLC Assay for Determination of Encapsulation Efficiency

References

• Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm 1997; 154: 123–140
   Web of Science ®Google Scholar
• Lasić DD. Novel applications of liposomes. Trends Biotechnol 1998; 16: 307–327
   PubMed Web of Science ®Google Scholar
• Gursoy A. Liposome-encapsulated antibiotics: physicochemical and antibacterial properties, a review. S.T.P. Pharma Sciences 2000; 10(4)285–291
   Google Scholar
• Pinto H, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrobial Agents 2000; 13: 155–168
   PubMedGoogle Scholar
• Massing U, Fuxius S. Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resistance Update 2000; 3: 171–177
   PubMed Web of Science ®Google Scholar
• Naessander UK, Storm G, Peeters P, Crommelin D. Liposomes. Biodegradable Polymers as Drug Delivery Systems, M. Chasin, R. Langer. Marcel Dekker, Inc., New York 1990; 261–338
   Google Scholar
• Alving CR. Liposomes as carriers of antigens and adjuvants. J Immunol Methods 1991; 140: 1–13
   PubMed Web of Science ®Google Scholar
• Alpar HO, Ward KR, Williamson ED. New strategies in vaccine delivery. S.T.P. Pharma Sciences 2000; 10(4)269–278
   Google Scholar
• Lian T, Ho RJY. Trends and development in liposome drug delivery systems. J Pharm Sci 2001; 90: 667–680
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Weidermann G, Jonas S, Althaus B, Finkel B, Gluck R, Herzog C. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15: 1209–1213
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, McCormack B, Obrenovic M, Saffie R, Zadi B, Perrie Y. Vaccine entrapment in liposomes. Methods 1999; 19: 156–162
   PubMed Web of Science ®Google Scholar
• Perrie Y, Gregoriadis G. Liposome-entrapped plasmid DNA: characterisation studies. Biochim Biophys Acta 2000; 1475: 125–132
   PubMed Web of Science ®Google Scholar
• Antimisiaris SG, Jayasekera P, Gregoriadis G. Liposomes as vaccine carriers. Incorporation of soluble and particulate antigens in giant vesicles. J Immunol Methods 1993; 166: 271–280
   PubMed Web of Science ®Google Scholar
• Killion JJ, Fidler IJ. Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome encapsulated immunomodulators. Pharmacol Ther 1998; 78: 141–154
   PubMed Web of Science ®Google Scholar
• Turanek J, Zaluska D, Vacek A, Borkovceva P, Thurnvaldova J, Blaha L, Mašek K. Stimulation of nonspecific immunity, haemopoiesis, and protection of mice against radiation injury by 1-adamantylamide-l-alanyl-d-isoglutamine incorporated in liposomes. Int Immunopharmacol 2001; 1: 167–175
   PubMedGoogle Scholar
• Krup OC, Kroll I, Boese G, Falkenberg FW. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation. J Immunother 1999; 22(6)525–538
   PubMedGoogle Scholar
• Vaccine adjuvants: Preparation Methods and Research Protocols. DT. O'Hagan. Humana Press, Totowa, New Jersey 2000; 342 pp.
   Google Scholar
• Giedlin MA. Cytokines As Vaccine Adjuvants: The Use of Interleukin-2. Vaccine adjuvants: Preparation Methods and Research Protocols, DT O'Hagan. Humana Press, Totowa, New Jersey 2000; 283–299
   Google Scholar
• Allison AC. The role of cytokines in the action of immunological adjuvants. Vaccine Design: The Role of Cytokine Networks, G. Gregoriadis, B. McCormack, AC. Allison. Plenum Press, New York 1997; 1–9
   Google Scholar
• Biological Properties of Peptidoglycans, PH. Seidl, KH. Schleifer. W. de Gruyter, Berlin 1986; 436 pp.
   Google Scholar
• Stewart-Tull DES. Immunostimulation with Peptidoglycan or its Synthetic Derivatives. Prog Drug Res 1988; 32: 305–328
   PubMedGoogle Scholar
• Tomašić J, Hanzl-Dujmović I, Špoljar B, Vranešić B, Šantak M, Jovičić A. Comparative study of the effects of peptidoglycan monomer and structurally related adamantyltripeptides on humoral immune response to ovalbumin in the mouse. Vaccine 2000; 18: 1236–1243
   PubMed Web of Science ®Google Scholar
• Ellouz F, Adam A, Ciorbaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 1974; 59: 317–325
   Google Scholar
• Azuma I. Synthetic immunoadjuvants: application to nonspecific host stimulation and potentation of vaccine immunogenicity Vaccine. 1992; 10: 1000–1006
   Google Scholar
• Urleb U, Krbavčič A, Sollner M, Kikelj D, Pečar S. Synthesis of phthalimido-desmuramylpeptide analogues as potential immunomodulating agents. Arch Pharm (Weinheim) 1995; 328: 113–117
   PubMed Web of Science ®Google Scholar
• Kikelj D, Pečar S, Kotnik V, Štalc A, Wraber-Herzog B, Simičič S, Ihan A, Klamfer L, Povšič L, Grahek R, Suhadolc E, Hočevar M, Honig H, Rogi-Kohlenprath R. N-(trans-2-((2′-(acetylamino)cyclohexyl(oxy(acetyl(-l-alanyl-d-glutamic acid: a novel immunologically active carbocyclic muramyl dipeptide analogue. J Med Chem 1998; 41: 530–539
   PubMedGoogle Scholar
• Keglević D, Ladešić B, Tomašić J, Valinger Z, Naumski R. Isolation procedure and properties of monomer unit from lysozyme digest of peptidoglycan complex excreted into the medium by penicillin-treated Brevibacterium divaricatum mutant. Biochim Biophys Acta 1979; 585: 273–281
   PubMed Web of Science ®Google Scholar
• Tomašić J, Sesartić Lj, Martin SA, Valinger Z, Ladešić B. Comparative susceptibility of a peptidoglycan monomer from Brevibacterium divaricatum and its anhydromuramyl analogue to hydrolysis with N-acetylmuramyl-l-alanine- amidase. J Chromatogr 1988; 440: 405–414
   PubMed Web of Science ®Google Scholar
• Matter H, Szilagyi L, Forgo P, Marinić. Ž, Klaić B. Structure and dynamics of a peptidoglycan monomer in aqueous solution using NMR spectroscopy and simulated annealing calculations. J Am Chem Soc 1997; 119: 2212–2223
   Web of Science ®Google Scholar
• Vranešić B, Ljevaković Đ, Tomašić J, Ladešić B. A competitive radioimmunoassay for peptidoglycan monomer. Clin Chim Acta 1991; 202: 23–38
   PubMedGoogle Scholar
• Hršak I, Ljevaković Đ, Tomašić J, Vranešić B. Preparation, properties and biological activity of tert-butyloxycarbonyl-l-tyrosyl peptidoglycan monomer. Immunotherapy of Infections, N Masihi. Marcel Dekker, New York 1994; 249–257
   Google Scholar
• Ljevaković Đ, Tomašić J, Šporec V, Halassy Špoljar B, Hanzl-Dujmović I. Synthesis of novel adamantylacetyl derivative of peptidoglycan monomer-biological evaluation of immunomodulatory peptidoglycan monomer and respective derivatives with lipophilic substituents on amino group. Bioorg Med Chem 2000; 8: 2441–2447
   PubMed Web of Science ®Google Scholar
• Vranešić B, Tomašić J, Smerdel S, Kantoci D, Benedetti F. Synthesis and antiviral activity of novel adamantyltripeptides. Helv Chim Acta 1993; 76: 1752–1758
   Google Scholar
• Sava G, Pacor S, Vranešić B, Tomašić J, Cocchietto M. Modification of the growth of MCa mammary carcinoma of CBA mouse by new adamantylpeptides. Int J Oncol 1993; 2: 607–612
   PubMedGoogle Scholar
• Dašić G, Pacor S, Bergamo A, Salerno G, Vranešić B, Jukić R, Tomašić J, Sava G. Effects of l-(adamant-2-yl)glycyl-l-alanyl-d-isoglutamine on the antitumor action of cyclophosphamide, 5-FU, cisplatin and dacarbazine on advanced carcinomas of the mouse. Int J Oncol 1994; 5: 275–281
   PubMedGoogle Scholar
• Vranešić B, Tomašić J, Ljevaković Đ, Hršak I. Biological activity of novel adamantyltripeptides with the emphasis on their immunorestorative effect. Immunotherapy of Infections, N Masihi. Marcel Dekker, Inc., New York 1994; 241–248
   Google Scholar
• Mažuran R, Vranešić B, Ikić-Sutlić M, Šimrak D, Tomašić J. Isomers of d,l-(adamant-2-yl)-glycyl-l-alanyl-d-isoglutamine induce intereferon production in human mononuclear cells. Period Biol 1996; 98(3)305–310
   Google Scholar
• Halassy Špoljar B, Čimbora T, Hanzl-Dujmović I, Dojnović B, Sabioncello A, Krstanović M, Tomašić J. Influence of adjuvant-active peptidoglycan monomer on specific T cell responses in mice. Vaccine 2002; 20: 3543–3550
   PubMed Web of Science ®Google Scholar
• Tomašić J, Ladešić B, Valinger Z, Hršak I. The metabolic fate of 14C-labeled peptidoglycan monomer in mice. I. Identification of the monomer and the corresponding pentapeptide in urine. Biochim Biophys Acta 1980; 629: 77–82
   PubMedGoogle Scholar
• Valinger Z, Ladešić B, Tomašić J. Partial purification and characterisation of N-acetylmuramyl-l-alanine amidase from human and mouse serum. Biochim Biophys Acta 1982; 701: 63–71
   PubMedGoogle Scholar
• Valinger Z, Ladešić B, Hršak I, Tomašić J. Relationship of metabolism and immunostimulating activity of peptidoglycan monomer in mice after three different routes of administration. Int J Immunopharmac 1987; 9: 325–332
   PubMedGoogle Scholar
• Halassy B, Krstanović M, Frkanec R, Tomašić J. Adjuvant activity of peptidoglycan monomer and its metabolic products. Vaccine 2003; 21: 971–976
   PubMed Web of Science ®Google Scholar
• Daemen T, Dontje BHJ, Regts J, Scherphof GL. Chemo-immunotherapy of murine liver metastases with 5-fluorouracil in combination with liposome-encapsulated muramyl dipeptide. J Immunother 1993; 13(1)31–35
   PubMed Web of Science ®Google Scholar
• Asano T, Matsushima K, Kleinerman ES. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels. Cancer Immunol Immunother 1994; 38: 16–22
   PubMed Web of Science ®Google Scholar
• Gianan MA, Kleinerman ES. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. Cancer Biother Radiopharm 1998; 13(5)363–368
   PubMed Web of Science ®Google Scholar
• Moribe K, Maruyama K, Iwatsuru M. Spectroscopic investigation of the molecular state of nystatin encapsulated in liposomes. Int J Pharm 2000; 201: 37–49
   PubMed Web of Science ®Google Scholar
• Canto GS, Dalmora SL, Oliveira AG. Piroxam encapsulated in liposomes: characterization and in vivo evaluation of topical anti-inflammatory effect. Drug Dev Ind Pharm 1999; 25(12)1235–1239
   PubMed Web of Science ®Google Scholar
• Youan BB, Benoit MA, Rollmann B, Riveau G, Gillard J. Protein-loaded poly(ε-caprolactone)microparticles. II. Muramyl dipeptide for oral controlled release of adjuvant. J Microencapsul 1999; 16(5)601–612
   PubMedGoogle Scholar
• Kirilenko VN, Gregoriadis G. Fat soluble vitamins in liposomes: studies on incorporation efficiency and bile salt induced vesicle disintegration. J Drug Target 1993; 1: 361–368
   PubMed Web of Science ®Google Scholar
• Ramaldes GA, Deverre JR, Grognet JM, Puisieux F, Fattal E. Use of an enzyme immunoassay for the evaluation of entrapment efficiency and in vitro stability in intestinal fluids of liposomal BSA. Int J Pharm 1996; 143: 1–11
   Google Scholar
• Lasić DD. Liposomes: From Physics to Applications. Elsevier, Amsterdam 1993; 559 pp.
   Google Scholar
• Tomašić J, Hršak I. Encapsulation of immunoadjuvant (14C(peptidoglycan monomer into liposomes. Effect on metabolism and immune response in mice. Biochim Biophys Acta 1982; 716: 217–223
   PubMedGoogle Scholar
• Krstanović M, Frkanec R, Vranešić B, Ljevaković Đ, Šporec V, Tomašić J. Reversed-phase high-performance liquid chromatographic method for the determination of peptidoglycan monomers and structurally related peptides and adamantyltripeptides. J Chromatogr B 2002; 773: 167–174
   PubMedGoogle Scholar
• Dipali SR, Kulkarni SB, Betageri GV. Comparative study of separation of non-encapsulated drug from unilamellar liposomes by various methods. J Pharm Pharmacol 1996; 48: 1112–1115
   PubMed Web of Science ®Google Scholar
• Frkanec R, Noethig-Laslo V, Mirosavljević K, Vranešić B, Tomašić J. A spin labeling study of immunomodulating peptidoglycan monomer and adamantyltripeptides entrapped into liposomes. Biochim Biophys Acta 2003; 1611: 187–196
   PubMed Web of Science ®Google Scholar